Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. (Q53598605)

16 May 2018

title

Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. (English)

1 reference

16 May 2018

author name string

Xiao Xiao He

1

1 reference

16 May 2018

Li Ding

2

1 reference

16 May 2018

Yuan Lin

3

1 reference

16 May 2018

Man Shu

4

1 reference

16 May 2018

Jian Ming Wen

5

1 reference

16 May 2018

Ling Xue

6

1 reference

16 May 2018

language of work or name

English

0 references

publication date

2 March 2015

1 reference

16 May 2018

Journal of Clinical Pathology

published in

1 reference

16 May 2018

volume

68

1 reference

16 May 2018

issue

5

1 reference

16 May 2018

page(s)

374-380

1 reference

16 May 2018

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

ErbB-3 predicts survival in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

HER3 is a determinant for poor prognosis in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Prognostic analysis of familial gastric cancer in Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

HER2 aberrations in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Low frequency of HER2 amplification and overexpression in early onset gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

High expression of HER3 is associated with a decreased survival in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

Expression and Nuclear Localization of ErbB3 in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202657

10.1136/JCLINPATH-2014-202657

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

PubMed ID

25731189

1 reference

16 May 2018